Last update 21 Nov 2024

Aripiprazole/Escitalopram

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Escitalopram/aripiprazole, OPC-14597/escitalopram
Target
5-HT1A receptor x 5-HT2A receptor x D2 receptor x D3 receptor x SERT
Mechanism
5-HT1A receptor agonists(Serotonin 1a (5-HT1a) receptor agonists), 5-HT2A receptor antagonists(Serotonin 2a (5-HT2a) receptor antagonists), D2 receptor agonists(Dopamine D2 receptor agonists)
+ [2]
Therapeutic Areas
Other Diseases
Active Indication-
Inactive Indication
Depressive Disorder, Major
Originator Organization
Otsuka Pharmaceutical Co., Ltd.Otsuka Pharmaceutical Co., Ltd.
Active Organization-
Inactive Organization
Otsuka Pharmaceutical Development & Commercialization, Inc.
Drug Highest PhasePendingPhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure

Molecular FormulaC20H21FN2O
InChIKeyWSEQXVZVJXJVFP-FQEVSTJZSA-N
CAS Registry128196-01-0
View All Structures (2)

Related

1
Clinical Trials associated with Aripiprazole/Escitalopram
NCT06433635 / Not yet recruitingPhase 4IIT
Sequential Multiple Assignment Randomized Trial for Bipolar Depression
100 Clinical Results associated with Aripiprazole/Escitalopram
Login to view more data
100 Translational Medicine associated with Aripiprazole/Escitalopram
Login to view more data
100 Patents (Medical) associated with Aripiprazole/Escitalopram
Login to view more data
100 Deals associated with Aripiprazole/Escitalopram
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Depressive Disorder, MajorPhase 3
SK
Otsuka Pharmaceutical Development & Commercialization, Inc.
03 Nov 2010
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
FDA_CDER
ManualManual
Not Applicable
Schizophrenia
-
(Study 1)
(xbwbqyzoxp) = jihlkuzudb ngnytgrdzp (brgvxutgqn, 2.40)
View more
Positive
22 Jul 2024
Aripiprazole (30 mg/day)
(Study 1)
(xbwbqyzoxp) = gpqzerjkkx ngnytgrdzp (brgvxutgqn, 2.39)
Pubmed | J Am Acad Child Adolesc Psychiatry
Not Applicable
Irritable Mood
-
(jwospetbws) = There were two serious adverse events: presyncope (5 mg/day) and aggression (10 mg/day) fprljcgtmv (ghouzyrpvd )
Positive
01 Nov 2009
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free